In-Flight Transmission of a SARS-CoV-2 Lineage B.1.617.2 Harbouring the Rare S:E484Q Immune Escape Mutation.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
28 02 2022
Historique:
received: 12 01 2022
revised: 24 02 2022
accepted: 25 02 2022
entrez: 26 3 2022
pubmed: 27 3 2022
medline: 1 4 2022
Statut: epublish

Résumé

We describe a flight-associated infection scenario of seven individuals with a B.1.617.2 (Delta) lineage, harbouring an S:E484Q point mutation. In Sweden, at least 10% of all positive SARS-CoV-2 samples were sequenced in each county; the B.1.717.2 + S:E484Q combination was not detected in Sweden before and was imported within the scenario described in this report. The high transmission rate of the delta lineage combined with the S:E484Q mutation, associated with immune escape in other lineages, makes this specific genetic combination a possible threat to the global fight against the COVID-19 pandemic. Even within the Omicron wave, the B.1.617.2 + S:E484Q variant appeared in community samples in Sweden, as it seems that this combination has an evolutionary gain compared to other B.1.617.2 lineages. The here described genomic combination was not detectable with the common fasta file-based Pango-lineage analysis, hence increasing the probability of the true global prevalence to be higher.

Identifiants

pubmed: 35336908
pii: v14030504
doi: 10.3390/v14030504
pmc: PMC8953675
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Knut and Alice Wallenberg Foundation
ID : KAW 2020.0241, High throughput SARS-CoV-2 variant surveillance
Organisme : VINNOVA
ID : Crush Covid
Organisme : Gullstrand foundation
ID : Development, evaluation and implementation of molecular epidemiological source tracing methods and variant sur-veillance

Références

Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Nucleic Acids Res. 2021 Jul 2;49(W1):W293-W296
pubmed: 33885785
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
Bioinformatics. 2012 Jun 15;28(12):1647-9
pubmed: 22543367
J Infect Dis. 2021 Sep 17;224(6):989-994
pubmed: 34260717
N Engl J Med. 2020 Mar 26;382(13):1278-1280
pubmed: 32069388
Bioinformatics. 2018 Sep 15;34(18):3094-3100
pubmed: 29750242
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
J Med Virol. 2021 Dec;93(12):6551-6556
pubmed: 34260088

Auteurs

Mats Martinell (M)

Primary Care and Health, Uppsala County Council, 75320 Uppsala, Sweden.
Department of Public Health and Caring Sciences, Uppsala University, 75237 Uppsala, Sweden.

Tanja Andersson (T)

Primary Care and Health, Uppsala County Council, 75320 Uppsala, Sweden.
Department of Public Health and Caring Sciences, Uppsala University, 75237 Uppsala, Sweden.

Steinar Smørholm Mannsverk (SS)

Clinical Microbiology and Hospital Hygiene, Uppsala University Hospital, 75237 Uppsala, Sweden.

Julia Bergholm (J)

Clinical Microbiology and Hospital Hygiene, Uppsala University Hospital, 75237 Uppsala, Sweden.

Patrik Ellström (P)

Clinical Microbiology and Hospital Hygiene, Uppsala University Hospital, 75237 Uppsala, Sweden.
Department of Medical Sciences, Clinical Microbiology, Uppsala University, 75236 Uppsala, Sweden.

Anna Hill (A)

Clinical Microbiology and Hospital Hygiene, Uppsala University Hospital, 75237 Uppsala, Sweden.

Johan Lindh (J)

Clinical Microbiology and Hospital Hygiene, Uppsala University Hospital, 75237 Uppsala, Sweden.
Department of Medical Sciences, Clinical Microbiology, Uppsala University, 75236 Uppsala, Sweden.
Science for Life Laboratory, Clinical Genomics Uppsala, 75237 Uppsala, Sweden.

Rene Kaden (R)

Department of Medical Sciences, Clinical Microbiology, Uppsala University, 75236 Uppsala, Sweden.
Science for Life Laboratory, Clinical Genomics Uppsala, 75237 Uppsala, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH